-

Vetoquinol Acquires the Rights for Profender® from Elanco Animal Health for Canada

LURE, France--(BUSINESS WIRE)--Regulatory News:

Vetoquinol (Paris:VETO) announced today the acquisition of the Canadian rights to Profender® product family from Elanco Animal Health.

Vetoquinol has acquired the Profender® product family, the intellectual property, registrations and other rights from Elanco Animal Health for the Canadian market. This acquisition has been approved by the Canadian Competion Bureau. The Profender® range consists in spot-on de-wormer products for cats.

In August 2020, Vetoquinol acquired the Profender® and Drontal® product families in the EU and the UK in relation to Elanco’s 2020 acquisition of Bayer AG’s animal health business. In January 2021, Vetoquinol also acquired the Profender® and Drontal® product families in Australia.

Matthieu Frechin, CEO of Vetoquinol, said: "We are very pleased to acquire Profender® for the Canadian market, one of our prominent strategic countries. The acquisition of this strong brand for the Canadian market confirms our ambition to become a major player in the parasiticide segment. Adding this Essential to our product portfolio in Canada will strengthen our market share in the pet segment in this strategic country.”

Next update: 2020 Annual results – April 1st 2021 before Market opening

ABOUT VETOQUINOL
Vetoquinol is a leading global animal health company that supplies drugs and non-medicinal products for the livestock (cattle and pigs) and pet (dogs and cats) markets.
As an independent pure player, Vetoquinol designs, develops and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region.
Since its foundation in 1933, Vetoquinol has been pursuing a strategy combining innovation with geographical diversification. The Group's hybrid growth is driven by the reinforcement of its product portfolio coupled with acquisitions in high potential growth markets. At December 31st 2020, Vetoquinol employs 2,409 people.
Vetoquinol has been listed on Euronext Paris since 2006 (symbol: VETO).

www.vetoquinol.com

Contacts

VETOQUINOL

Investor Relations
Fanny Toillon
Tel.: +33 (0)3 84 62 59 88
relations.investisseurs@vetoquinol.com

KEIMA COMMUNICATION

Investor & Media Relations
Emmanuel Dovergne
Tel.: +33 (0) 1 56 43 44 63
emmanuel.dovergne@keima.fr

Vetoquinol

BOURSE:VETO
Release Versions
EnglishFrench

Contacts

VETOQUINOL

Investor Relations
Fanny Toillon
Tel.: +33 (0)3 84 62 59 88
relations.investisseurs@vetoquinol.com

KEIMA COMMUNICATION

Investor & Media Relations
Emmanuel Dovergne
Tel.: +33 (0) 1 56 43 44 63
emmanuel.dovergne@keima.fr

More News From Vetoquinol

Vetoquinol: 2025 Annual Sales

LURE, France--(BUSINESS WIRE)--Regulatory News: In an economy marked by unusual exchange rate volatility, Vetoquinol (Paris:VETO) achieved two important objectives: growth in Essential products and internalization of the manufacturing of the parasiticide range. Vetoquinol's sales for FY 2025 came to €525.7 million, up 0.2% at constant exchange rates and down 2.5% on a reported basis. Over the financial year, the company recorded historically high negative currency impacts of €14.8 million in al...

Vetoquinol: Sales at End September 2025

LURE, France--(BUSINESS WIRE)--Regulatory News: At the end of September 2025, Vetoquinol's (Paris:VETO) sales amounted to €384.2 million, down 3.5% on a reported basis and down 1.3% at constant exchange rates. Over this period, the Group recorded net negative currency impacts of €8.9 million in the Americas and Asia-Pacific/Rest of the World regions and an impact of - €7.7 million from the simplification of complementary ranges, mainly in Europe. Net of these two items, sales for the first nine...

Vetoquinol: 2025 Half Year Results

LURE, France--(BUSINESS WIRE)--Regulatory News: The Board of Directors of Vetoquinol SA (Paris:VETO), meeting on September 9, 2025, approved the financial statements for the first half of the 2025 financial year. The limited review report on the financial statements as of June 30, 2025, was issued by the Statutory Auditors. Vetoquinol's sales amounted to €258 million for the first six months of fiscal year 2025. Sales of Essentials products amounted to €165 million, up 4.2% at constant exchange...
Back to Newsroom